Phio Pharmaceuticals

Phio Pharmaceuticals, based in Marlborough, Massachusetts, is a clinical-stage biotech company co-founded by a Nobel Prize-winning scientist. The company's core mission is to advance cancer immunotherapy through innovative RNA interference (RNAi) technologies. Phio's proprietary INTASYL® platform enhances the effectiveness of immune cells in targeting and destroying tumor cells. Their market focus is primarily on developing treatments for various types of cancer, leveraging their cutting-edge RNAi solutions.

Notable affiliated individuals include the Nobel Prize-winning co-founder who discovered RNA interference. Phio Pharmaceuticals has attracted significant attention and investment due to its groundbreaking approach to cancer treatment. Key achievements include the development and clinical progression of their INTASYL® technology, which has shown promise in preclinical and early clinical trials. The overall impact of Phio Pharmaceuticals lies in its potential to revolutionize cancer immunotherapy, offering new hope for more effective and targeted cancer treatments.